Study of Pharmacological Treatment in Women With Female Sexual Interest/Arousal Disorder (FSIAD).

计划入组 80 人 · 首次发布于 2020 年 6 月 16 日

Study to Evaluate the Effectiveness and Safety of Libicare® in Women With Low Arousal and Sexual Desire Levels

首次发布于 2019 年 12 月 6 日

Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause

计划入组 150 人 · 首次发布于 2026 年 2 月 13 日

autologous adipose derived mesenchymal stem cell therapy (female sexual dysfunction)

ALTO-102 + ALTO-103 + ALTO-104

PS-778629

AICHI HEALTH PROMOTION PUBLIC INTEREST FOUNDATION

Japan

THE PARKINSON'S AND MOVEMENT DISORDER INSTITUTE

United States

Creative Medical Technology

United States

Arletta Pharma Secures FDA Endorsement for Lybrido Phase 2 Program, Eyes Streamlined Path to NDA for Female Sexual Interest/Arousal Disorder

Freya Pharma Launches Phase II Study of Lybrido for Female Sexual Dysfunction Using Novel Blood Flow Measurement

Arletta Pharma's Lybrido™ Shows Statistically Significant Improvement in Female Sexual Dysfunction Phase II Trial